Antiviral for AIDS reverse transcriptase inhibitor

Drugs of the Future

Volumn 23, Issue 2, 1998, Pages 133-141

  Graul, A ^a   Rabasseda, X ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CD4 ANTIGEN; CLARITHROMYCIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; INDINAVIR; LAMIVUDINE; LOVIRIDE; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0031944616     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.02.445974     Document Type: Review

References (33)

1. Thompson, A.S., Corley, E.G., Grabowski, E.J.J., Yasuda, N. (Merck & Co., Inc.). Asymmetric synthesis of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1- benzoxazin-2-one. WO 9637457.
2. Thompson, A.S., Corley, E.G., Huntington, M. (Merck & Co., Inc.). Improved synthesis of cyclopropylacetylene. WO 9622955.
3. Thompson, A.S., Corley, E.G., Huntington, M.F., Grabowski, E.J.J. Use of an ephedrine alkoxide to mediate enantioselective addition of an acetylide to a prochiral ketone: Asymmetric synthesis of the reverse transcriptase inhibitor L-743,726. Tetrahedron Lett 1995, 36: 8937-40.
4. Young, S.D., Tran, L.O., Britcher, S.F., Lumma, W.C. Jr., Payne, L.S. (Merck & Co., Inc.). Benzoxazinones as inhibitors of HIV reverse transcriptase. EP 582455. JP 94184124, WO 9403440.
5. Young, S.D., Britcher, S.F., Payne, L.S., Tran, L.O., Lumma, W.C. Jr. (Merck & Co., Inc.). Benzoxazinones as inhibitors of HIV reverse transcriptase. WO 9520389.
6. Young, S.D., Britcher, S.F., Tran, L.O. et al. L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995, 39: 2602-5.
7. Barry, M., Mulcahy, F., Back, D.J. Antiretroviral therapy for patients with HIV disease. Brit J Clin Pharmacol 1998, 45: 221-8.
8. Young, S.D. et al. L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.A.1077.
9. Winslow, D.L., Garber, S., Reid, C., Scarnati, H., Korant, B., Emini, E., Anton, E.D. Development of high-level resistance to DMP 266 requires multiple mutations in the reverse transcriptase gene. J Acq Immune Defic Syndromes Hum Retrovirol 1995, 10(Suppl. 3): Abst 13.
10. Fiske, W.D., Brennan, J.M., Haines, P.J., Mutlib, A.E., Gemzik, B., Gerson, R. Efavirenz (DMP 266) cerebrospinal fluid (CSF) concentrations after chronic oral administration to cynomolgus monkeys. 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 640.
11. Balani, S.K., Kauffman, L.R., Lin, J.H. Pharmacokinetics of L-743,726 (DMP-266), an HIV-1 reverse transcriptase inhibitor, in rats and monkeys. 7th North Amer ISSX Meet (Oct 20-24, San Diego) 1996, Abst 268.
12. Bacheler, L.T., Anton, E., Baker, D., Cordova, B., Fiske, W., Garber, S., Logue, K., Rizzo, C., Tritch, R., Erickson-Vittanen, S. Impact of mutation, plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 non nucleoside reverse transcriptase inhibitor, DMP 266. 37th lntersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst 1-115.
13. Mayers, D., Riddler, S., Stein, D., Bach, M., Havir, D., Kahn, J. A double-blind pilot study to evaluate the antiviral activity, tolerability and pharmacokinetics of DMP 266 alone and in combination with indinavir. 36th lntersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst LB8a.
14. Fiske, W.D., Mayers, D., Wagner, K. et al. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
15. Fiske, W.D., Benedek, I.H., White, S.J., Joseph, J.L., Kornhauser, D.M. Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate (NFV) in healthy volunteers. 37th lntersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst 1-174.
16. Fiske, W.D., Benedek, I.H., White, S.J., Pepperess, K.A., Joseph, J.L., Kornhauser, D.M. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers. 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 349.
17. Piscitelli, S., Vogel, S., Sadler, B., Fiske, W., Metcalf, J., Masur, H., Falloon, J. Effect of efavirenz (DMP 266) on the pharmacokinetics of 141W94 in HIV-infected patients. 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 346.
18. Benedek, I.H., Joshi, A., Fiske, W.D., White, S.J., Jobes, J.L., Joseph, J.L., Kornhauser, D.M. Pharmacokinetic (PK) interaction studies in healthy volunteers with efavirenz (EFV) and the macrolide antibiotics, azithromycin (AZM) and clarithromycin (CLR). 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 347.
19. Joshi, A.S., Fiske, W.D., Benedek, I.H., White, S.J., Joseph, J.L., Kornhauser, D.M. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers. 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 348.
20. Riddler, S., Mayers, D., Wagner, K. et al. A double-blind pilot study to evaluate the antiviral activity, tolerability of DMP 266 alone and in combination with indinavir. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
21. ™) in combination with open-label zidovudine (ZDV) with lamivudine (3TC) [DMP 266-005]. 6th Eur Conf Clin Aspects Treat HIV Infect (Oct 11-15, Hamburg) 1997, Abst.
22. ™) in combination with open-label zidovudine (ZDV) with lamivudine (3TC [DMP-266-005]. 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 698.
23. ® assay in patients receiving indinavir +/-DMP 266 (efavirenz). Results of DMP-266-003, cohort IV. 6th Eur Conf Clin Aspects Treat HIV Infect (Oct 11-15, Hamburg) 1997, Abst.
24. ® as a predictor for virologic treatment response [DMP 266-003, cohort IV]. 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 692.
25. Mayers, D., Riddler, S., Bach, M. et al. Durable clinical anti-HIV-1 activity and tolerability for DMP 266 in combination with indinavir (IDV) at 24 weeks. 37th lntersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst 1-175.
26. ® assay receiving indinavir ± DMP 266 (efavirenz). 6th Eur Conf Clin Aspects Treat HIV Infect (Oct 11-15, Hamburg) 1997, Abst.
27. ®. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst I-172.
28. ™ (efavirenz, DMP 266). 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 702.
29. Winslow, D.L., Garber, S., Reid, C., Scarnati, H., Baker, D., Rayner, M.M., Anton, E.D. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 1996, 10: 1205-9.
30. ™) in vivo. 5th Conf Retroviruses Opportunistic Infect (Feb 1-5, Chicago) 1998, Abst 703.
31. 3 now have access to Sustiva. DuPont Merck Pharmaceutical Co. Press Release 1997, December 17.
32. Gupta, P., Mellors, J., Kingsley, L., Riddler, S., Singh, M.K., Schreiber, S., Cronin, M., Rinaldo, C.R. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997, 71: 6271-5.
33. Rayner, M.M., Cordova, B., Jackson, D.A. Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections. Virology 1997, 236: 85-94.